🟢 Rezolute Inc is trading 12% up today after positive interim Phase 3 data for ersodetug

Rezolute Inc is trading 12% up at $4.49 in pre-market following positive interim Phase 3 upLIFT data for its drug ersodetug in tumor hyperinsulinism.

• The clinical milestone showed that patients were able to stop IV glucose treatment, a significant efficacy marker often rewarded by rare-disease biotech investors.
• The pre-market surge extends a period of strong momentum for the stock, which has climbed from $3.25 to $4.00 over the past week.